Sogroya is used as replacement therapy in adults who do not produce enough growth hormone (growth hormone deficiency). It is also used to treat children and adolescents who are not growing at the normal rate as a result of growth hormone deficiency and is given to patients from 3 years of age. Growth hormone deficiency is rare, and Sogroya was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 24 August 2018. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3182068](http://ema.europa.eu/medicines/human/orphan-designations/eu3182068). Sogroya contains the active substance somapacitan.
Therapeutic Indication
### Therapeutic indication Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
Therapeutic Area (MeSH)
N/AATC Code
H01AC07
ATC Item
somapacitan
Pharmacotherapeutic Group
Pituitary and hypothalamic hormones and analogues
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| somapacitan | N/A | Somapacitan |
| Somapacitan | N/A | Somapacitan |
EMA Name
Sogroya
Medicine Name
Sogroya
Aliases
N/ANo risk management plan link.
